

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

**UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA**

E.H. and C.S., *on behalf of themselves and
all others similarly situated,*

Plaintiffs,

v.

META PLATFORMS, INC.,
Defendant.

Case No. 3:23-cv-04784-WHO

**PLAINTIFFS' REPLY IN SUPPORT OF
THEIR MOTION FOR LEAVE TO
AMEND THEIR COMPLAINT**

Action Filed: September 18, 2023

Honorable Judge William H. Orrick

INTRODUCTION

Plaintiffs contend the scope of this case has been clear all along; it covers the claims of all non-Facebook users whose sensitive, protected health information Meta stole for profit. Following Judge DeMarchi's recent Motion to Compel ruling, however, Plaintiffs moved to amend their Complaint to clarify the scope. Plaintiffs' Proposed First Amended Complaint (the "PFAC," ECF No. 96-1 Ex. A) removes any ambiguity identified by Judge DeMarchi. To defeat Plaintiffs' Motion to Amend, Meta bears a heavy burden: it must show that the PFAC is futile or prejudicial despite the extremely liberal standard of Rule 15, under which amendments are presumptively granted. *PNY Techs., Inc. v. SanDisk Corp.*, 2014 WL 294855, at *4 (N.D. Cal. Jan. 27, 2014) (Orrick, J.). Meta has not come close to meeting its burden.

First, the correct standard for evaluating Plaintiffs' Motion to Amend is Fed. R. Civ. P. 12(b)(6), and because the PFAC's additional factual allegations state a plausible claim for relief, the amendment is proper. Meta never addresses this. Instead, Meta relies exclusively on Judge DeMarchi's Rule 26 Motion to Compel Order (ECF No. 93) to argue that the PFAC is futile. Their argument conflates a Rule 26 discovery order with the liberal amendment standard of Rule 15, which are not the same. *See Nordyke v. King*, 644 F.3d 776, 788 n.12 (9th Cir. 2011) (holding that an amended complaint is futile only if "it would be immediately subject to dismissal." (internal

1 quotations omitted)), *modified en banc on other grounds by* 681 F.3d 1041 (9th Cir. 2012). Judge
 2 DeMarchi’s ruling did *not* decide the legal sufficiency of the PFAC, and in fact, she consistently
 3 recognized that the scope of the Complaint—as opposed to a discovery dispute—was a decision for
 4 this Court.

5 Applying the appropriate standard, the PFAC is not futile. As this Court has already held (ECF
 6 No. 56) Plaintiffs plausibly alleged all of their claims. Plaintiffs’ PFAC also makes clear that this
 7 conduct was not limited to Plaintiffs or to any one covered entity. Meta’s widespread interceptions of
 8 protected health information were consistent with the design and purpose of the Pixel, as well as
 9 Meta’s broader business strategy for indiscriminately collecting and monetizing every scrap of
 10 personal information it could harvest. At the pleading stage, no further level of specificity is required.
 11 *See Sepehry-Fard v. Dept. Stores Nat’l Bank*, 2013 WL 6574774, at *1-2 (N.D. Cal. Dec. 13, 2013)
 12 (Orrick, J.) (explaining that “courts do not require ‘heightened fact pleading of specifics’” at the
 13 motion to dismiss stage). In another attempt to insert class certification issues into the Rule 15
 14 analysis, Meta also challenges Plaintiffs’ standing to represent the class. This argument is both
 15 unsupported by case law and premature.

16 *Second*, Meta argues that the PFAC causes prejudice in the form of additional discovery. But
 17 amendments typically result in additional discovery, and that is not the type of prejudice that Rule 15
 18 forbids. Rather, courts have consistently held that the mere prospect of additional discovery does not
 19 constitute “prejudice” in the face of a timely amendment. *See e.g., PNY Techs.*, 2014 WL 294855, at
 20 *4 (citing *Tyco Thermal Controls LLC v. Redwood Indus.*, 2009 WL 4907512, at *3 (N.D. Cal. Dec.
 21 14, 2009); *Genentech, Inc. v. Abbott Labs.*, 127 F.R.D. 529, 531 (N.D. Cal. 1989)). Rule 15 prejudice
 22 is caused by surprise or an untimely amendment. *Dep’t of Fair Emp. & Hous. v. Law Sch. Admission*
 23 *Council, Inc.*, 2013 WL 485830, at *5-6 (N.D. Cal. Feb. 6, 2013). Neither situation is present here.

24 In short, Meta has not met its heavy burden. Instead, Meta’s opposition illustrates its all-out
 25 efforts to delay the progression of this case. It has been *over 18 months* since Plaintiffs filed their
 26 class action complaint, and yet Meta has failed to produce a *single document* in discovery—even on
 27 claims (such as Cerebral) that indisputably will go forward. Meta has filibustered, engaging in endless
 28

1 meet and confers. Before Judge DeMarchi, Meta raised for the first time standing arguments that only
 2 this Court can decide. Now, in front of this Court, Meta insists that this Motion is about discovery
 3 issues (it is not) that Judge DeMarchi already decided (she did not). Thus, Plaintiffs ask the Court to
 4 grant their Motion to Amend, and order Meta to move forward forthwith.

5 ARGUMENT

6 I. Plaintiffs' Proposed First Amended Complaint is Not Futile.

7 Meta first claims that the PFAC is futile. Meta bears the burden of establishing that assertion.
 8 *PNY Techs.*, 2014 WL 294855, at *4. The “futility” analysis mirrors that of Rule 12(b)(6). *Nordyke*,
 9 644 F.3d at 788 n.12. The court must “accept[] the plaintiff’s allegations as true and draw[] all
 10 reasonable inferences in favor of the plaintiff.” *Codexis, Inc. v. EnzymeWorks, Inc.*, 2017 WL
 11 4236860, at *4 (N.D. Cal. Sept. 25, 2017) (Orrick, J.). This is a “high standard,” *Staley v. Gilead*
 12 *Sciences*, 2021 WL 5906049, at *3 (N.D. Cal. Dec. 14, 2021), and thus, “[c]ourts rarely deny a motion
 13 for leave to amend for reason of futility,” particularly when discovery has not been completed, *Hynix*
 14 *Semiconductor Inc. v. Toshiba Corp.*, 2006 WL 3093812, at *2 (N.D. Cal. Oct. 31, 2006).

15 A. The PFAC’s new factual allegations state a claim.

16 Despite this well-established law, Meta does not address Rule 12(b)(6). It claims instead that
 17 the PFAC does not cure the deficiencies identified in Judge DeMarchi’s discovery order. ECF No.102
 18 (“Opp’n”) at 4. But the scope of discovery is not at issue here. Judge DeMarchi evaluated a different
 19 complaint under a different rule: Rule 26. Order at 2. Judge DeMarchi recognized this distinction and
 20 was clear that she could not decide the scope of the Complaint under Rule 12(b)(6). *See* Dec. 3, 2024
 21 Hr’g Tr. At 3:22-25 (“I’m not really sure that this dispute is about discovery. I think the dispute is,
 22 principally, about what is Plaintiffs’ complaint about, and I’m not sure this question is properly
 23 addressed to me.”), *and id.* at 12:11–15 (“I don’t think this issue has ever been raised to Judge
 24 Orrick. . . ‘What is the scope?’ It was not decided.”); *see also id.* at 12:19-20 (“I don’t think I’m the
 25 right person to decide what the scope of the complaint is.”). The scope of the PFAC is now properly
 26 before this Court. Meta, however, has failed to even argue the correct standard. This alone dooms its
 27
 28

1 position. *Curry Mgt. Corp. v. JP Morgan Chase Bank, NA*, 643 F. Supp. 3d 421, 426 (S.D.N.Y. 2022)
 2 (“A party may be deemed to concede an argument by failing to address it in an opposition brief.”).

3 Even if this were not true, Meta has not met its burden under Rules 15 and 12(b)(6). First,
 4 Meta mischaracterizes the PFAC’s new factual allegations. The original Complaint did not name
 5 individual Covered Entities other than Cerebral and Monument. Order at 2. The PFAC cures this.
 6 Appendix A to the PFAC lists the relevant “Covered Entities” and confirms that they “transmitted
 7 sensitive and protected health information as set out in the Class Definition” PFAC ¶¶ 41-44.
 8 The PFAC explains that the Pixel allows *all* Covered Entities—not just *Cerebral and Monument*—to
 9 transmit protected information of unnamed Class Members. PFAC ¶¶ 1-9. The PFAC also alleges
 10 that an average of 25 million transmissions every day triggered the system that Meta built to identify
 11 (but not halt) transmissions of sensitive health information, underscoring the widespread nature of
 12 Meta’s interceptions from covered entities. PFAC ¶ 65. Clearly, all 25 million did not come from
 13 Cerebral or Monument alone.

14 The PFAC also clarifies that the class definition includes only those non-Facebook users who
 15 provided protected information to a Covered Entity. PFAC ¶ 11. Plaintiffs and putative class members
 16 were not “simply surfing the web seeking information about routine or general healthcare topics.”
 17 Order Denying Mot. to Dismiss, ECF No. 56 at 4.¹ The Court previously recognized that these
 18 allegations state a claim against Meta with respect to Cerebral. The PFAC’s new allegations—which
 19 the Court accepts as true—make clear that the Class is not limited to Cerebral. Plaintiffs’ theory is
 20 “facially plausible” and raises claims that are well above the speculative level. *Sepehry-Fard*, 2013
 21 WL 6574774, at *1-2. This is all that Rules 15 and 12(b)(6) require. *See id.*

22
 23
 24 ¹ Notably, Plaintiffs’ counsel manually confirmed that the Meta Pixel on each Covered Entities’
 25 website was transmitting protected information to Meta. They examined records of the Pixel’s
 26 transmissions from each website to verify that the information being transmitted showed that the user
 27 was trying to schedule an appointment, created an account, filled out forms, or was otherwise
 28 affirmatively seeking care. *See* PFAC ¶¶ 35, 39, 40, 43 (describing Meta Pixel interception of this
 type of data from Covered Entities). They also verified that the information transmitted either itself
 contained health information or constituted health information in conjunction with the services
 provided by the covered entity. *See* Order Denying Mot. to Dismiss, ECF No. 56 at 4 (“[I]
 information, some of which would ordinarily not be protected, plausibly becomes sensitive or private
 considering that plaintiffs were seeking mental health services.”).

1 Second, the PFAC need not—as Meta contends—allege how “all [Covered Entities] used the
 2 Meta Pixel improperly to send protected health information.” Opp’n at 5. Plaintiffs’ complaint is
 3 aimed at Meta’s conduct, not that of any Covered Entity. *See* PFAC ¶ 11. Plaintiffs allege that Meta’
 4 used its Pixel technology to become an unseen invader in their medical care, violating multiple state
 5 and federal privacy and consumer protection laws. Meta repeatedly refers to “misuse” of the pixel by
 6 third parties, but the only malfeasance at issue in this case is Meta’s. Opp’n at 1, 6. Similarly, Meta
 7 refers to Plaintiffs’ claims against third parties, but the only entity Plaintiffs have brought claims
 8 against is Meta. Opp’n at 6. Much though it might wish to, Meta cannot write itself out of Plaintiffs’
 9 complaint.

10 The litany of factual information Meta seeks about unnamed class members’ interactions with
 11 Covered Entities is also not required at this stage of the case. Opp’n at 5. These are matters for
 12 discovery and class certification. The Ninth Circuit has been clear that “a class action, when filed,
 13 includes only the claims of the named plaintiff or plaintiffs,” and the unnamed class members are
 14 added to the case only after certification.² *Gibson v. Chrysler Corp.*, 261 F.3d 297 (9th Cir. 2001).
 15 Even if that were not the case, Rule 12(b)(6) does not require “heightened fact pleading.” *Sepehry*,
 16 2013 WL 6574774, at *1.

17 Meta relies on *Doe I v. Google LLC*, 741 F. Supp. 3d 828 (N.D. Cal. 2024), but *Doe I* changes
 18 nothing. The *Doe I* court acknowledged that its decision might conflict with this Court’s decision on
 19 the *issue of intent*. *Id.* at 841. Meta, however, does not raise that issue in its Opposition. Nor has it
 20 moved the Court to reconsider its previous ruling. *See also Doe v. Meta Platforms, Inc.*, 2024 WL
 21 4375776, at *2 (N.D. Cal. Oct. 2, 2024) (Orrick, J.) (denying certification of interlocutory appeal on
 22 the basis of *Doe I* and stating that the facts alleged about Meta’s Pixel interceptions differed from
 23 those alleged in *Doe I*). Even if it had, the Court got it right the first time. Issues of intent are ill-suited
 24 for decisions under Rule 12(b)(6). “[Q]uestions of intent, should be left to the jury.” *Harris v. Itzhaki*,

25
 26 ² For the same reason, it is entirely unsurprising that the Court’s order on the motion to dismiss
 27 specifically mentioned the Covered Entity used by both named plaintiffs—their individual claims
 28 were the only claims at issue. Meta’s insinuations to the contrary ignore both this procedural reality
 and the fact that Meta’s motion was expressly limited to the named plaintiffs. *see* ECF No. 34 at 2
 (defining “Plaintiffs” as named Plaintiffs E.H. and C.S.).

1 183 F.3d 1043, 1051 (9th Cir. 1999); *In re Twitter, Inc. Sec. Litig.*, 2020 WL 9073168, at *3 (N.D.
2 Cal. Apr. 20, 2020) (same).

3 Nor does this case suffer from the deficiencies identified in *Doe I*. The court in *Doe I*, for
4 example, noted that the named plaintiffs used imprecise language about the type of information
5 transmitted to Google. 741 F. Supp. 3d at 839. The PFAC, however, contains precise allegations about
6 what information was transmitted. The PFAC also states that the Pixel transfers information including
7 “specific prescriptions, diagnoses, and symptoms” PFAC ¶ 1. It likewise states that this happened
8 to the named Plaintiffs. *Id.* ¶ 7. The PFAC further alleges that the Class includes only those whose
9 shared personally identifying information, healthcare questionnaire information, booking and billing
10 information, and other protected health information. *Id.* ¶ 11. *Compare infra*, with *Doe I*, 741 F. Supp.
11 3d at 839 (“the plaintiffs repeatedly allege that data sent to Google ‘may include’ specific information
12 like patient device identifiers or search terms.”).

13 **B. Plaintiffs have standing to bring claims on behalf of the class.**

14 Finally, Meta—without explicitly saying so—raises a standing argument. Meta claims that
15 the PFAC does not satisfy the “substantial similarity” test this Court adopted in *Ang v. Bimbo Bakeries*
16 *USA, Inc.*, 2014 WL 1024182, at *8 (N.D. Cal. Mar. 13, 2014). Yet, even a cursory reading of *Ang*
17 reveals that the test is a poor fit here. There is only one product at issue in this case: the Meta Pixel.

18 But even if the test were applicable, Plaintiffs satisfy it. In *Ang*, the Court held that a class can
19 include different products (here different websites) so long “the type of claim and consumer injury
20 [are] substantially similar.” 2014 WL 1024182, at *8. In the context of class claims, the Court should
21 not “employ too narrow or technical an approach . . . [or] parse too finely” *Id.* at *4 (quoting
22 *Armstrong v. Davis*, 275 F.3d 849, 867 (9th Cir. 2001), *abrogated on other grounds by Johnson v.*
23 *California*, 543 U.S. 499, 504–05 (2005)). So long as the “legal analysis of the claim[s]” is the same,
24 the test is satisfied. *Id.* at *9. That is certainly true in this case. All of the claims of all putative class
25 members, as well as their injuries, are virtually identical. *Infra* page 4-5. The legal analysis from
26 Covered Entity to Covered Entity will not change anything about class members’ claims as to Meta.
27 Additionally, the class members themselves have the same relationship to and injury from Meta that
28

1 Plaintiffs do: hidden, unconsented invasion by Meta into their medical care. *Cf. Eastman v. Quest*
 2 *Diagnostics Inc.*, 108 F. Supp. 3d 827, 833 (N.D. Cal. 2015) (Orrick, J.) (finding that individual
 3 patient plaintiffs did not have standing to bring claims on behalf of corporation health care plans
 4 because of the latter’s distinctive relationship to the defendant). This satisfies the test. *See id.*

5 In any event, whether Plaintiffs’ claims are typical of the Class is a question for class
 6 certification, not this Rule 15 Motion. In the Ninth Circuit, courts may evaluate the legal distinctions
 7 between the named Plaintiff and unnamed class members prior to certification when the named
 8 plaintiffs raise claims under jurisdictions where they were not harmed. *In re Glumetza Antitrust Litig.*,
 9 611 F. Supp. 3d 848, 866-67 (N.D. Cal. 2020). They do not, however, evaluate *factual* disjunctures
 10 between the claims of the named plaintiff and unnamed class members until the Rule 23 stage.
 11 *Melendres v. Arpaio*, 784 F.3d 1254, 1262 (9th Cir. 2015). “[T]he dissimilarity of circumstances
 12 raised within the same claim [is] ‘relevant only to class certification, not to standing.’” *Glumetza*, 611
 13 F. Supp. 3d at 866 (quoting *Melendres*, 784 F.3d at 1257-58); *see also Nunez v. Saks Inc.*, 771 Fed.
 14 Appx. 401 (9th Cir. 2019) (applying *Melendres* to violations of California consumer protection laws);
 15 *B.K. ex rel. Tinsley v. Snyder*, 922 F.3d 957 (9th Cir. 2019) (applying *Melendres* to constitutional
 16 violations and violations of the Medicaid Act); *Kirola v. City and County of San Francisco*, 860 F.3d
 17 1164 (9th Cir. 2017) (applying *Melendres* to violations of the Americans with Disabilities Act).
 18 Instead, *before* class certification, “once the named plaintiff demonstrates her individual standing to
 19 bring a claim, the standing inquiry is concluded.” *Melendres*, 784 F.3d at 1262. This forecloses Meta’s
 20 claims that Plaintiffs must provide detailed allegations about unnamed class members at this stage.

21 II. The PFAC is Not Prejudicial.

22 As with futility, Meta bears the burden of showing that amendment at this juncture would be
 23 prejudicial. *Codexis*, 2017 WL 4236860, at *3. “To overcome Rule 15(a)’s liberal policy with respect
 24 to the amendment of pleadings a showing of prejudice must be substantial.” *Stearns*, 763 F. Supp. 2d
 25 at 1158. The relevant prejudice is typically surprise or untimeliness that robs a defendant of the
 26 requisite time to mount a defense. When there is ample time and opportunity for discovery, there is
 27 no prejudice. *Codexis*, 2017 WL 4236860, at *2. Thus, as Plaintiffs noted in their opening papers,
 28

1 DATED: March 17, 2025

2 **MOTLEY RICE LLC**

3 s/Abigail Burman

4 Previn Warren*
5 Abigail Burman*
6 401 9th Street NW Suite 630
7 Washington DC 20004
8 Tel: 202-386-9610
9 pwarren@motleyrice.com
10 aburman@motleyrice.com

11 Mathew Jasinski*
12 One Corporate Center
13 20 Church St., 17th Floor
14 Hartford, CT 06103
15 mjasinski@motleyrice.com

16 Lance Oliver*
17 Max Gruetzmacher*
18 28 Bridgeside Blvd
19 Mt. Pleasant, SC 29464
20 loliver@motleyrice.com
21 mgruetzmacher@motleyrice.com

22 *APPEARANCE PRO HAC VICE
23
24
25
26
27
28

**ADAMSKI MOROSKI MADDEN
CUMBERLAND & GREEN LLP**

JAMES M. WAGSTAFFE
STEVEN J. ADAMSKI
Mailing Address: PO Box 3835
San Luis Obispo, CA 93403-3835
Physical Address: 6633 Bay Laurel Pl.
Avila Beach, CA 93424
Telephone: (805) 543-0990
wagstaffe@ammcglaw.com
adamski@ammcglaw.com